Eli Lilly and (NYSE:LLY) released its quarterly earnings data on Tuesday. The company reported $1.34 EPS for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.21, Bloomberg Earnings reports. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The firm had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.51 billion. During the same period in the previous year, the business posted $0.98 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. Eli Lilly and updated its FY18 guidance to $5.10-5.20 EPS.
LLY opened at $80.20 on Tuesday. Eli Lilly and has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01. The stock has a market cap of $86,617.97, a P/E ratio of 18.74, a PEG ratio of 1.44 and a beta of 0.26.
In related news, CFO Joshua L. Smiley sold 3,000 shares of the company’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $79.20, for a total transaction of $237,600.00. Following the completion of the sale, the chief financial officer now owns 20,029 shares of the company’s stock, valued at $1,586,296.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Susan Mahony sold 22,544 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $80.09, for a total value of $1,805,548.96. Following the transaction, the senior vice president now directly owns 45,652 shares of the company’s stock, valued at approximately $3,656,268.68. The disclosure for this sale can be found here. Insiders have sold 42,970 shares of company stock valued at $3,444,557 in the last ninety days. 0.11% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Gradient Investments LLC acquired a new position in Eli Lilly and during the fourth quarter worth about $103,000. Avestar Capital LLC acquired a new position in Eli Lilly and during the fourth quarter worth about $100,000. Front Row Advisors LLC acquired a new position in Eli Lilly and during the fourth quarter worth about $137,000. Wealthcare Advisory Partners LLC acquired a new position in Eli Lilly and during the third quarter worth about $142,000. Finally, Fieldpoint Private Securities LLC acquired a new position in Eli Lilly and during the third quarter worth about $147,000. 77.69% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on LLY shares. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and boosted their target price for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Tuesday, January 16th. Goldman Sachs cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their target price for the company from $86.98 to $95.00 in a research report on Tuesday, January 16th. Credit Suisse Group cut shares of Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 target price for the company. in a research report on Monday, January 22nd. Finally, JPMorgan Chase set a $105.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. One analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. Eli Lilly and currently has an average rating of “Buy” and an average target price of $93.16.
WARNING: This report was reported by Macon Daily and is the property of of Macon Daily. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://macondaily.com/2018/04/24/eli-lilly-and-lly-issues-earnings-results.html.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.